Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Wally Mastroly who wrote (3444)	4/24/1998 8:46:00 AM
From: Hal	Read Replies (1) \| Respond to of 3906

The upgrade is because Viagra has safety and efficacy issues. Below! Cruttenden Roth raised its rating on VIVUS INC. to strong buy from neutral and set a 1998 price target on the stock of $23 a share. And said it believes Pfizer Inc's anti-impotence drug Viagra has safety and efficacy issues which will limit the patient base the product can treat. Also said Vivus will be well positioned to take advantage of erectile dysfunction patients who Viagra may not be able to treat successfully. And estimated that Viagra may only be effective in 50 percent of erectile dysfunction patients and that those you find it ineffective may turn to Vivus' MUSE treatment for impotence. Said Vivus' new production facility, expected to come online in mid-1998, will allow it to reap rewards from Pfizer's marketing campaign which will likely increase the number of men seeking drugs for erectile dysfunction. (Reuters 02:22 PM ET 04/23/98)